Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Weide Zhong"'
Autor:
Ren Liu, Zhihao Zou, Lingwu Chen, Yuanfa Feng, Jianheng Ye, Yulin Deng, Xuejin Zhu, Yixun Zhang, Jundong Lin, Shanghua Cai, Zhenfeng Tang, Yingke Liang, Jianming Lu, Yangjia Zhuo, Zhaodong Han, Xiaohui Ling, Yuxiang Liang, Zongren Wang, Weide Zhong
Publikováno v:
Cell Death and Disease, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Renal cell carcinoma (RCC) is one of the three major malignant tumors of the urinary system and originates from proximal tubular epithelial cells. Clear cell renal cell carcinoma (ccRCC) accounts for approximately 80% of RCC cases and is rec
Externí odkaz:
https://doaj.org/article/6891daa6392c4c2e9cf958ebc5a5ad49
Autor:
Maozhang Li, Guangwei Bai, Yi Cen, Qitong Xie, Jiahong Chen, Jia Chen, Qingbiao Chen, Weide Zhong, Xiaobo Zhou
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-14 (2023)
Abstract Background Advanced prostate cancer (PCa) will develop into castration-resistant prostate cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR accounts for the major induction of PCa heterogeneity. CRPC-AR is mai
Externí odkaz:
https://doaj.org/article/bdf2b566c9984f1c9df31ba9c362cf60
Autor:
Jianheng Ye, Shanghua Cai, Yuanfa Feng, Jinchuang Li, Zhiduan Cai, Yulin Deng, Ren Liu, Xuejin Zhu, Jianming Lu, Yangjia Zhuo, Yingke Liang, Jianjiang Xie, Yanqiong Zhang, Huichan He, Zhaodong Han, Zhenyu Jia, Weide Zhong
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-15 (2023)
Abstract The therapeutic efficacy of metformin in prostate cancer (PCa) appears uncertain based on various clinical trials. Metformin treatment failure may be attributed to the high frequency of transcriptional dysregulation, which leads to drug resi
Externí odkaz:
https://doaj.org/article/2376bd6bb3a54b9a98270b5490f976eb
Autor:
Xiao Tan, Zhouda Cai, Guo Chen, Chao Cai, Jiahong Chen, Yingke Liang, Yangjia Zhuo, Jianming Liu, Liangliang Huang, Bin Ouyang, Yanni Wei, Zhenyu Jia, Junhong Deng, Weide Zhong, Jianming Lu
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-20 (2023)
Abstract Objectives Due to the heterogeneity of PCa, the clinical indicators used for PCa can't satisfy risk prognostication and personalized treatment. It is imperative to develop novel biomarkers for prognosis prediction and therapy response in PCa
Externí odkaz:
https://doaj.org/article/9231e9ca4ccd4ca58c702f2211e9f8bb
Autor:
Qingling Xie, Ren Liu, Zhihao Zou, Yuanfa Feng, Yiqiao Huang, Guibin Xu, Wei Sun, Yuxiang Liang, Weide Zhong
Publikováno v:
FEBS Open Bio, Vol 12, Iss 11, Pp 2083-2095 (2022)
Myosin phosphatase target subunit 1 (MYPT1) is a subunit of myosin phosphatase that is capable of regulating smooth muscle contraction. MYPT1 has been reported to be involved in a wide variety of tumours, but its expression and biological functions i
Externí odkaz:
https://doaj.org/article/88019a0142884fc3aa52971b52feaea6
Autor:
Hongxiang Liu, Yong Luo, Shankun Zhao, Jing Tan, Minjian Chen, Xihai Liu, Jianheng Ye, Shanghua Cai, Yulin Deng, Jinchuang Li, Huichan He, Xin Zhang, Weide Zhong
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundClear cell renal cell carcinoma (ccRCC) is a malignant disease containing tumor-infiltrating lymphocytes. Reactive oxygen species (ROS) are present in the tumor microenvironment and are strongly associated with cancer development. Neverthel
Externí odkaz:
https://doaj.org/article/f45e4641bc9146c2a6ca7a4ee9a0077b
Autor:
Jianming Lu, Jiahong Chen, Zhuoyuan Lin, Qinwei Liu, Chuanfan Zhong, Zhouda Cai, Zhenyu Jia, Weide Zhong, Yingke Liang, Chao Cai
Publikováno v:
Translational Oncology, Vol 33, Iss , Pp 101670- (2023)
Novel biomarkers are urgently needed to improve the prediction of clinical outcomes and guide personalized treatment for prostate cancer (PCa) patients. However, the role of N6-methyladenosine (m6A) modifications in PCa initiation and progression rem
Externí odkaz:
https://doaj.org/article/e7a882712efa46fe9f09f31745b6acd7
Publikováno v:
Mathematical Biosciences and Engineering, Vol 19, Iss 11, Pp 11345-11366 (2022)
The aim of this study is to construct an inflammatory response-related genes (IRRGs) signature to monitor biochemical recurrence (BCR) and treatment effects in prostate cancer patients (PCa). A gene signature for inflammatory responses was constructe
Externí odkaz:
https://doaj.org/article/53b33658ad6e4f318b51439b5b5f9ee3
Autor:
Jie Zeng, Jiahong Chen, Maozhang Li, Chuanfan Zhong, Zezhen Liu, Yan Wang, Yuejiao Li, Funeng Jiang, Shumin Fang, Weide Zhong
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Metastatic castration-resistant prostate cancer (mCRPC) is a highly aggressive stage of prostate cancer, and non-mutational epigenetic reprogramming plays a critical role in its progression. Super enhancers (SE), epigenetic elements, are
Externí odkaz:
https://doaj.org/article/55a0b7d904284d2baebba47942631f43
Autor:
Yuanfa Feng, Yulin Deng, Zhenfeng Tang, Shanghua Cai, Jinchuang Li, Ren Liu, Jiaming Wan, Huichan He, Guohua Zeng, Jianheng Ye, Zhaodong Han, Weide Zhong
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
BackgroundEnzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is prominent representative among the synthetic androgen receptor antagonists. Currently, there is lack of enzalutamide-induced signature (ENZ-sig) for p
Externí odkaz:
https://doaj.org/article/91c2612ac6424a91be51dcd91b1e24bf